ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Profiling people with Parkinson's disease at risk of cognitive decline: Insights from PPMI and ICICLE-PD data.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Cognition endpoints for Parkinson's disease: A roadmap for developing patient-focused assessment tools to accelerate drug development.Journal of Parkinson's disease · 2026Article
- Predicting Cognition and Affective Changes in Newly Diagnosed Parkinson's Disease Through Longitudinal Data-Driven Clustering.Journal of geriatric psychiatry and neurology · 2026Article
- Prevention of cognitive impairment and dementia in people with Parkinson's disease: A call-to-action.Journal of Parkinson's disease · 2025Review
- Cortical volumetry and longitudinal cognitive changes in Parkinson's disease: insights from the COPPADIS cohort.Brain imaging and behavior · 2025Article
- Subtyping Early Parkinson's Disease by Mapping Cognitive Profiles to Brain Atrophy with Visual MRI Ratings.Brain sciences · 2025Article
- Can we detect cognitive "super-agers" in Parkinson's disease? Cognitive, neuropsychiatric and motor outcomes in the first 10 years of Parkinson's disease.Parkinsonism & related disorders · 2025Article
- Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy.Frontiers in neurology · 2024Article
- What can we do to enhance cognitive care in Parkinson's disease?Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Profiling people with Parkinson's disease at risk of cognitive decline: Insights from PPMI and ICICLE-PD data.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Introduction: A subset of people with Parkinson's disease (PD) develop dementia faster than others. We aimed to profile PD cognitive subtypes at risk of dementia based on their rate of cognitive decline. Method: Latent class mixed models stratified subtypes in Parkinson's Progression Markers Initiative (PPMI) ( Results: Four subtypes were identified: two with stable cognition, one with steady decline, and one with rapid decline. Performance on Judgement of Line Orientation, but not category fluency, was associated with a steady decline in the PPMI dataset, and deficits in category fluency, but not visuospatial function, were associated with a steady decline in the ICICLE-PD dataset. Discussion: People with PD susceptible to cognitive decline demonstrate unique clinical profiles at diagnosis, although this differed between cohorts. Highlights: Four cognitive subtypes were revealed in two Parkinson's disease samples.Unique profiles of cognitive impairment were related to cognitive decline.Judgement of Line Orientation/category fluency predictive of steady decline.Global deficits related to rapid cognitive decline and increased dementia risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.